Which is the pharma stock that will benefit most from the new crown

According to current earnings, the pharmaceutical stock that would benefit most from the new crown would be Fosun Pharmaceuticals. According to the first quarter of 2021, the company achieved operating income of 8.056 billion yuan, net profit of 658 million yuan, earnings per share of 0.3300 yuan, price-earnings ratio of 50.18. May 9, Fosun Pharmaceuticals announced that its subsidiary intends to set up a joint venture with BioNTech to achieve the localization of the production of the mRNA vaccine for the new crown and commercialization. As a pharmaceutical stock, Fosun Pharmaceuticals shares took advantage of the stimulus of the new crown vaccine quickly soared, market value once exceeded 200 billion.

1, the new crown vaccine industry stocks other than: Hualan biological, Tianhua super clean, Tai Lin biological, new Lai should material, Changhong Meiling, Aucma, Haier biological, Haiyong cold chain, Zhifei biological, State Pharmaceuticals, Sai Sheng pharmaceuticals and so on. New crown vaccine concept stocks other: Watson biology, Kangdelei, Chutian technology, Jin Lei shares, Kangtai biology, Wantai biology, Ruipu biology, Dongfeng shares, Tibet Pharmaceuticals, unnamed medicine, JieTe biology and so on.

2, the new crown generally refers to the new coronavirus pneumonia. New coronavirus pneumonia, referred to as "new coronavirus pneumonia", the World Health Organization named "2019 coronavirus disease", refers to 2019 new coronavirus infection caused by pneumonia. 2019 new coronavirus infection since December 2019, Wuhan City, Hubei Province, part of the hospital one after another. Several cases of unexplained pneumonia with a history of exposure to the South China Seafood Market were found and confirmed to be an acute respiratory infectious disease caused by 2019 novel coronavirus infection.

3. According to the available case information, the new coronavirus pneumonia is mainly manifested by fever, dry cough and malaise, and a few patients are accompanied by upper respiratory and digestive tract symptoms such as nasal congestion, runny nose and diarrhea. In severe cases, respiratory distress occurs after 1 week, and in severe cases, it rapidly progresses to acute respiratory distress syndrome, septic shock, uncorrectable metabolic acidosis and hemorrhagic coagulation dysfunction and multi-organ failure. It is worth noting that severe and critically ill patients may have low to moderate fever during the course of the disease, or even no obvious fever. Mild patients only show low fever, mild fatigue, etc., without pneumonia. From the current admissions, most patients have a good prognosis, and a few patients are in critical condition. Elderly people and those with chronic underlying diseases have a poorer prognosis. Children's cases have relatively mild symptoms.

4. Tip: Information related to pharmaceutical stocks will cause changes in the stock, the data is for reference only, investment should be cautious.